02 June 2017 / article

Borderline products: Cranberry products cannot be regarded as medical devices

The European Commission’s Regulatory Committee on Medical Devices has adopted a Commission Decision on the qualification of cranberry products.

According to the Decision, cranberry products do not fall within the definition of medical devices set out in the Medical Devices Directive.  

The European Commission’s Regulatory Committee on Medical Devices has adopted a Commission Implementing Decision on the qualification of cranberry products. The Decision states that products “whose principal intended action, depending on proanthocyanidins present in cranberry (Vaccinium Macrocarpon)extract, is to prevent or treat cystitis”, are not medical devices within the meaning of Article 1 (2) (a) of the Medical Devices Directive.

Pharmacological and not a mechanical

The Decision was taken upon the request from France in accordance with Article 13 (1) (d) of the Medical Devices Directive. It also follows the European Medicines Agency’s (EMA) scientific opinion of 22 July 2016 which noted that “Products containing proanthocyanidins and/or cranberry as substance or preparation for use in urinary tract infections are currently marketed differently across the EU as food supplement, medical device or consumer product”. Furthermore, EMA concluded that the principal intended action of this group of products is most probably pharmacological and not a mechanical mode which would qualify them as medical devices.

Food supplements or medicinal products?

It will nevertheless be up to the Members States’ competent authorities to determine whether these products are food supplements or medicinal products. Should they be considered as food supplements, all health-related communications regarding those products will fall within the scope of the Nutrition and Health Claims Regulation.

The formal adoption and publication of the Decision are planned later this summer.

EMA’s revised guidelines on first-in-human clinical trials to increase safety of trial participants

EMA’s revised guidelines on first-in-human clinical trials to increase safety of trial participants

The European Medicines Agency (EMA) has published its revised guideline on first-in-human clinical trials. The revision of the guideline is the result of the...
read more
European supervisors issue warning on Initial Coin Offerings

European supervisors issue warning on Initial Coin Offerings

European financial supervisors published warnings on the risks of Initial Coin Offerings to investors and on the rules for firms involved in ICO
read more
Commission proposal: Gas Directive to include gas pipelines to and from third countries

Gas Directive to include gas pipelines to and from third countries

The European Commission presented its proposal to update Directive 2009/73/EC (the “Gas Directive”).
read more